Supernus Pharmaceuticals Inc

Research Supernus Pharmaceuticals Inc (SUPN) on Bullrun: market cap USD 2.72B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSUPN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Market capUSD 2.72B
• Financial periodFY2025
• RevenueUSD 718.95M
• Revenue growth8.6%
• Net income-USD 38.60M
• Free cash flowUSD 45.99M
• Gross margin89.6%

Valuation Snapshot

latest market cap is USD 2.72B.

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD);

Frequently asked questions

What is Supernus Pharmaceuticals Inc's market cap?

Supernus Pharmaceuticals Inc's market capitalization is USD 2.72B.

What does Supernus Pharmaceuticals Inc do?

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.